Skip to main content
Top
Published in: Current Psychiatry Reports 12/2013

01-12-2013 | Schizophrenia and Other Psychotic Disorders (SJ Siegel, Section Editor)

Use of Antipsychotic Medications in Pediatric Populations: What do the Data Say?

Authors: Robert B. Penfold, Christine Stewart, Enid M. Hunkeler, Jeanne M. Madden, Janet R. Cummings, Ashli A. Owen-Smith, Rebecca C. Rossom, Christine Y. Lu, Frances L. Lynch, Beth E. Waitzfelder, Karen A. Coleman, Brian K. Ahmedani, Arne L. Beck, John E. Zeber, Gregory E. Simon

Published in: Current Psychiatry Reports | Issue 12/2013

Login to get access

Abstract

Recent reports of antipsychotic medication use in pediatric populations describe large increases in rates of use. Much interest in the increasing use has focused on potentially inappropriate prescribing for non-Food and Drug Administration-approved uses and use amongst youth with no mental health diagnosis. Different studies of antipsychotic use have used different time periods, geographic and insurance populations of youth, and aggregations of diagnoses. We review recent estimates of use and comment on the similarities and dissimilarities in rates of use. We also report new data obtained on 11 health maintenance organizations that are members of the Mental Health Research Network in order to update and extend the knowledge base on use by diagnostic indication. Results indicate that most use in pediatric populations is for disruptive behaviors and not psychotic disorders. Differences in estimates are likely a function of differences in methodology; however, there is remarkable consistency in estimates of use by diagnosis.
Literature
1.
go back to reference Olfson M, Crystal S, Huang C, Gerhard T. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry. 2010;49:13–23.PubMed Olfson M, Crystal S, Huang C, Gerhard T. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry. 2010;49:13–23.PubMed
2.
go back to reference • Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69:1247–56. The article presents antipsychotic utilization estimates between 1993 and 2009 using nationally representative NAMCS data. Estimates are based on visits where a prescription occurred. Excellent discussion of reasons for practice variation in prescribing and increasing use over time.PubMedCrossRef • Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69:1247–56. The article presents antipsychotic utilization estimates between 1993 and 2009 using nationally representative NAMCS data. Estimates are based on visits where a prescription occurred. Excellent discussion of reasons for practice variation in prescribing and increasing use over time.PubMedCrossRef
3.
go back to reference • Andrade SE, Lo JC, Roblin D, Fouayzi H, Connor DF, Penfold RB, et al. Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics. 2011;128:1135–41. Study reports an almost fourfold increase in the rate of diabetes among youth using antipsychotic medications compared to youth using no psychotropic medications.PubMedCrossRef • Andrade SE, Lo JC, Roblin D, Fouayzi H, Connor DF, Penfold RB, et al. Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics. 2011;128:1135–41. Study reports an almost fourfold increase in the rate of diabetes among youth using antipsychotic medications compared to youth using no psychotropic medications.PubMedCrossRef
4.
go back to reference • Correll CU. Safety and tolerability of antipsychotic treatment in young patients with schizophrenia. J Clin Psychiatry. 2011;72:e26. Seminal study on the side effects of antipsychotic medications in youth.PubMedCrossRef • Correll CU. Safety and tolerability of antipsychotic treatment in young patients with schizophrenia. J Clin Psychiatry. 2011;72:e26. Seminal study on the side effects of antipsychotic medications in youth.PubMedCrossRef
5.
go back to reference • Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21:517–35. Review of 34 published head-to-head and placebo-controlled studies in youth with psychotic and bipolar disorders of the effects of antipsychotic medications on weight and metabolic disorders. Describes metabolic effects and number-needed-to-harm for individual agents.PubMedCrossRef • Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21:517–35. Review of 34 published head-to-head and placebo-controlled studies in youth with psychotic and bipolar disorders of the effects of antipsychotic medications on weight and metabolic disorders. Describes metabolic effects and number-needed-to-harm for individual agents.PubMedCrossRef
6.
go back to reference Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. J Clin Psychopharmacol. 2012;32:309–16.PubMedCrossRef Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. J Clin Psychopharmacol. 2012;32:309–16.PubMedCrossRef
7.
go back to reference • Seida JC, Schouten JR, Boylan K, Newton AS, Mousavi SS, Beaith A, et al. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics. 2012;129:e771–84. Reviews the comparative effectiveness of individual agents for youth across 64 trials and 17 cohort studies.PubMedCrossRef • Seida JC, Schouten JR, Boylan K, Newton AS, Mousavi SS, Beaith A, et al. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics. 2012;129:e771–84. Reviews the comparative effectiveness of individual agents for youth across 64 trials and 17 cohort studies.PubMedCrossRef
8.
go back to reference Loy JH, Merry SN, Hetrick SE, Stasiak K. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev. 2012;9, CD008559.PubMed Loy JH, Merry SN, Hetrick SE, Stasiak K. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev. 2012;9, CD008559.PubMed
9.
go back to reference • McKinney C, Renk K. Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations. Clin Psychol Rev. 2011;31:465–71. Discusses mechanisms of action and long-term outcomes for young people using antipsychotics. Good discussion of use for sedation rather than core reasons for disruptive behavior.PubMedCrossRef • McKinney C, Renk K. Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations. Clin Psychol Rev. 2011;31:465–71. Discusses mechanisms of action and long-term outcomes for young people using antipsychotics. Good discussion of use for sedation rather than core reasons for disruptive behavior.PubMedCrossRef
10.
go back to reference Harrison JN, Cluxton-Keller F, Gross D. Antipsychotic medication prescribing trends in children and adolescents. J Pediatr Health Care. 2012;26:139–45.PubMedCentralPubMedCrossRef Harrison JN, Cluxton-Keller F, Gross D. Antipsychotic medication prescribing trends in children and adolescents. J Pediatr Health Care. 2012;26:139–45.PubMedCentralPubMedCrossRef
11.
go back to reference Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359–69.PubMedCrossRef Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359–69.PubMedCrossRef
12.
go back to reference Penfold RB, Kelleher KJ, Wang W, Strange B, Pajer K. Pediatric uptake of a newly available antipsychotic medication. Pediatrics. 2010;125:475–82.PubMedCrossRef Penfold RB, Kelleher KJ, Wang W, Strange B, Pajer K. Pediatric uptake of a newly available antipsychotic medication. Pediatrics. 2010;125:475–82.PubMedCrossRef
13.
go back to reference • Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf. 2011;20:177–84. Only recent study estimating use from physician-reported prescribing. Categorizes the volume of off-label use by level of evidence.PubMedCentralPubMedCrossRef • Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf. 2011;20:177–84. Only recent study estimating use from physician-reported prescribing. Categorizes the volume of off-label use by level of evidence.PubMedCentralPubMedCrossRef
14.
go back to reference Hassler F, Reis O. Pharmacotherapy of disruptive behavior in mentally retarded subjects: a review of the current literature. Dev Disabil Res Rev. 2010;16:265–72.PubMedCrossRef Hassler F, Reis O. Pharmacotherapy of disruptive behavior in mentally retarded subjects: a review of the current literature. Dev Disabil Res Rev. 2010;16:265–72.PubMedCrossRef
15.
go back to reference Aman MG, Gharabawi GM, Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental R, Developmental D. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. J Clin Psychiatry. 2004;65:1197–210.PubMedCrossRef Aman MG, Gharabawi GM, Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental R, Developmental D. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. J Clin Psychiatry. 2004;65:1197–210.PubMedCrossRef
16.
go back to reference McDougle CJ, Stigler KA, Erickson CA, Posey DJ. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry. 2008;69 Suppl 4:15–20.PubMed McDougle CJ, Stigler KA, Erickson CA, Posey DJ. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry. 2008;69 Suppl 4:15–20.PubMed
17.
go back to reference Capone GT, Goyal P, Grados M, Smith B, Kammann H. Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study. J Dev Behav Pediatr. 2008;29:106–16.PubMedCrossRef Capone GT, Goyal P, Grados M, Smith B, Kammann H. Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study. J Dev Behav Pediatr. 2008;29:106–16.PubMedCrossRef
18.
go back to reference • Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009;28:w770–81. Compares antipsychotic utilization in both Medicaid (public) and MarketScan (commercial) data.CrossRef • Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009;28:w770–81. Compares antipsychotic utilization in both Medicaid (public) and MarketScan (commercial) data.CrossRef
19.
go back to reference • dos Reis S, Yoon Y, Rubin DM, Riddle MA, Noll E, Rothbard A. Antipsychotic treatment among youth in foster care. Pediatrics. 2011;128(6):e1459–66. Compares utilization among youth eligible for Medicaid on the basis of disability or low income to youth in foster care.CrossRef • dos Reis S, Yoon Y, Rubin DM, Riddle MA, Noll E, Rothbard A. Antipsychotic treatment among youth in foster care. Pediatrics. 2011;128(6):e1459–66. Compares utilization among youth eligible for Medicaid on the basis of disability or low income to youth in foster care.CrossRef
20.
go back to reference •• Matone M, Localio R, Huang YS, Dosreis S, Feudtner C, Rubin D. The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. medicaid-enrolled children. Health Serv Res. 2012;47:1836–60. Comprehensive presentation of utilization rates in youth across 50 states and 6 years. Detailed rates available for young people aged 0–5, 6–11, and 12–18 years.PubMedCrossRef •• Matone M, Localio R, Huang YS, Dosreis S, Feudtner C, Rubin D. The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. medicaid-enrolled children. Health Serv Res. 2012;47:1836–60. Comprehensive presentation of utilization rates in youth across 50 states and 6 years. Detailed rates available for young people aged 0–5, 6–11, and 12–18 years.PubMedCrossRef
21.
go back to reference Ellis WR, Huebner C, Vander Stoep A, Williams MA. Washington State exhibits wide regional variation in proportion of Medicaid-eligible children who get needed mental health care. Health Aff (Millwood). 2012;31:990–9.CrossRef Ellis WR, Huebner C, Vander Stoep A, Williams MA. Washington State exhibits wide regional variation in proportion of Medicaid-eligible children who get needed mental health care. Health Aff (Millwood). 2012;31:990–9.CrossRef
22.
go back to reference Cummings JR, Wen H, Ko M, Druss BG. Geography and the Medicaid mental health care infrastructure: implications for health care reform. JAMA Psychiatry. 2013;70:1084–90.PubMedCrossRef Cummings JR, Wen H, Ko M, Druss BG. Geography and the Medicaid mental health care infrastructure: implications for health care reform. JAMA Psychiatry. 2013;70:1084–90.PubMedCrossRef
23.
go back to reference Harris E, Sorbero M, Kogan JN, Schuster J, Stein BD. Concurrent mental health therapy among medicaid-enrolled youths starting antipsychotic medications. Psychiatr Serv. 2012;63:351–6.PubMed Harris E, Sorbero M, Kogan JN, Schuster J, Stein BD. Concurrent mental health therapy among medicaid-enrolled youths starting antipsychotic medications. Psychiatr Serv. 2012;63:351–6.PubMed
24.
go back to reference Sturm R, Ringel JS, Andreyeva T. Geographic disparities in children's mental health care. Pediatrics. 2003;112:e308.PubMedCrossRef Sturm R, Ringel JS, Andreyeva T. Geographic disparities in children's mental health care. Pediatrics. 2003;112:e308.PubMedCrossRef
25.
go back to reference Merikangas KR, He JP, Rapoport J, Vitiello B, Olfson M. Medication use in US youth with mental disorders. JAMA Pediatr. 2013;167:141–8.PubMedCrossRef Merikangas KR, He JP, Rapoport J, Vitiello B, Olfson M. Medication use in US youth with mental disorders. JAMA Pediatr. 2013;167:141–8.PubMedCrossRef
26.
go back to reference • Olfson M, He JP, Merikangas KR. Psychotropic medication treatment of adolescents: results from the national comorbidity survey-adolescent supplement. J Am Acad Child Adolesc Psychiatry. 2013;52:378–88. Estimates rates of antipsychotic use in youth across socio-demographic groups. Diagnoses were obtained using a validated instrument rather than administrative codes.PubMedCrossRef • Olfson M, He JP, Merikangas KR. Psychotropic medication treatment of adolescents: results from the national comorbidity survey-adolescent supplement. J Am Acad Child Adolesc Psychiatry. 2013;52:378–88. Estimates rates of antipsychotic use in youth across socio-demographic groups. Diagnoses were obtained using a validated instrument rather than administrative codes.PubMedCrossRef
27.
go back to reference Simon GE, Rutter CM, Stewart C, Pabiniak C, Wehnes L. Response to past depression treatments is not accurately recalled: comparison of structured recall and patient health questionnaire scores in medical records. J Clin Psychiatry. 2012;73:1503–8.PubMedCentralPubMedCrossRef Simon GE, Rutter CM, Stewart C, Pabiniak C, Wehnes L. Response to past depression treatments is not accurately recalled: comparison of structured recall and patient health questionnaire scores in medical records. J Clin Psychiatry. 2012;73:1503–8.PubMedCentralPubMedCrossRef
28.
go back to reference Solomon DH, Stedman M, Licari A, Weinblatt ME, Maher N, Shadick N. Agreement between patient report and medical record review for medications used for rheumatoid arthritis: the accuracy of self-reported medication information in patient registries. Arthritis Rheum. 2007;57:234–9.PubMedCrossRef Solomon DH, Stedman M, Licari A, Weinblatt ME, Maher N, Shadick N. Agreement between patient report and medical record review for medications used for rheumatoid arthritis: the accuracy of self-reported medication information in patient registries. Arthritis Rheum. 2007;57:234–9.PubMedCrossRef
29.
go back to reference Boudreau DM, Daling JR, Malone KE, Gardner JS, Blough DK, Heckbert SR. A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. Am J Epidemiol. 2004;159:308–17.PubMedCrossRef Boudreau DM, Daling JR, Malone KE, Gardner JS, Blough DK, Heckbert SR. A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. Am J Epidemiol. 2004;159:308–17.PubMedCrossRef
30.
go back to reference van Gelder MM, van Rooij IA, de Walle HE, Roeleveld N, Bakker MK. Maternal recall of prescription medication use during pregnancy using a paper-based questionnaire: a validation study in the Netherlands. Drug Saf. 2013;36:43–54.PubMedCrossRef van Gelder MM, van Rooij IA, de Walle HE, Roeleveld N, Bakker MK. Maternal recall of prescription medication use during pregnancy using a paper-based questionnaire: a validation study in the Netherlands. Drug Saf. 2013;36:43–54.PubMedCrossRef
31.
go back to reference West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol. 1995;142:1103–12.PubMed West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol. 1995;142:1103–12.PubMed
Metadata
Title
Use of Antipsychotic Medications in Pediatric Populations: What do the Data Say?
Authors
Robert B. Penfold
Christine Stewart
Enid M. Hunkeler
Jeanne M. Madden
Janet R. Cummings
Ashli A. Owen-Smith
Rebecca C. Rossom
Christine Y. Lu
Frances L. Lynch
Beth E. Waitzfelder
Karen A. Coleman
Brian K. Ahmedani
Arne L. Beck
John E. Zeber
Gregory E. Simon
Publication date
01-12-2013
Publisher
Springer US
Published in
Current Psychiatry Reports / Issue 12/2013
Print ISSN: 1523-3812
Electronic ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-013-0426-8

Other articles of this Issue 12/2013

Current Psychiatry Reports 12/2013 Go to the issue

Personality Disorders (C Schmahl, Section Editor)

Antisocial Personality Disorder: A Current Review

Eating Disorders (AS Kaplan, Section Editor)

Genetics of Eating Disorders